Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Assets (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Non-Current Assets for 8 consecutive years, with $991.6 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets rose 137.58% year-over-year to $991.6 million; the TTM value through Mar 2026 reached $2.8 billion, up 71.91%, while the annual FY2025 figure was $871.6 million, 86.33% up from the prior year.
  • Non-Current Assets hit $991.6 million in Q1 2026 for Kymera Therapeutics, up from $871.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $991.6 million in Q1 2026 and bottomed at $120.7 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $361.7 million, with a median of $300.6 million recorded in 2024.
  • Year-over-year, Non-Current Assets decreased 7.23% in 2023 and then skyrocketed 174.44% in 2024.
  • Kymera Therapeutics' Non-Current Assets stood at $183.7 million in 2022, then fell by 7.23% to $170.4 million in 2023, then surged by 174.44% to $467.8 million in 2024, then skyrocketed by 86.33% to $871.6 million in 2025, then rose by 13.77% to $991.6 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $991.6 million, $871.6 million, and $573.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.